Ranbaxy hormone to cure osteoporosis

By admin |

3rd April 2008

Hyderabad: Good news for aging people suffering from osteoporosis! Ranbaxy Laboratories on Thursday launched recombinant human parathyroid hormone ‘Bonista- Teriparatide' injection for the treatment of the disease, in collaboration with Virchow Biotech. According to the company, the product has been indigenously researched at Virchow in Hyderabad and developed in association with the Department of Science and Technology in India. Commenting on the launch of the product, Ranbaxy Senior VP and Regional Director (Asia and CIS) Sanjeev I Dani said that with growing longevity, Osteoporosis a condition characterised by loss of bone mass, would gain increased attention. Dani claimed that Bonista is a quality bio-generic therapeutic options to doctors and an affordable and efficacious product to patients. According to the company, with the life span of an average Indian going up, the country is witnessing an increase in the number of osteoporosis cases; with an estimated 50 per cent Indian women having osteoporosis, the actual number translates to over 30 million. Experts suggests that one of the reasons could be that the majority of Indians have low vitamin D status and are on low dietary calcium which makes them prone to bone diseases. —iGovernment Bureau
comments powered by Disqus
CIL and Centre ink MoA for training

CIL to train 1.7 lakh people

Delhi LG asks to refer all files to him

Reference to LG as per GNCTD Act and business rules

CCI to step up vigil on high technology market...

To boost its vigil against unfair business ways

latest opinion

Local Government Cloud Adoption – Time to make...

Rajeev Saxena

Director Sales, India Public Sector, Commercial and SAARC , NetApp India
'New Generation Governance': Transforming India...

Virender Jeet

Sr. VP Technology , Newgen Software
e-Biz Portal Goes Live

Sanjay Kumar

Senior Assistant Editor , Nine Dot Nine Mediaworx

survey & reports